Identification of 5-methylisoxazole-4-carboxylic acid and 4-(trifluoromethyl)aniline degradation products for leflunomide by high-performance thin-layer chromatography coupled with high-resolution mass spectrometry

被引:0
作者
Ghante, M. R. [1 ]
Sawant, S. R. [1 ]
Bhusari, V. K. [1 ]
Sawant, S. D. [2 ]
Jagtap, S. S. [2 ]
机构
[1] Smt Kashibai Navale Coll Pharm, Dept Pharmaceut Qual Assurance, Sinhgad Tech Educ Soc, Pune, India
[2] Smt Kashibai Navale Coll Pharm, Dept Pharmaceut Chem, Sinhgad Tech Educ Soc, Pune, India
关键词
Leflunomide; High-performance thin-layer chromatographic (HPTLC); High-resolution mass spectrometry (HR-MS); Forced degradation; Validation; INDICATING HPLC METHOD;
D O I
10.1007/s00764-022-00214-z
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
This study details the developed high-performance thin-layer chromatographic (HPTLC) method for estimating the active pharmaceutical ingredient of leflunomide and its formulation. HPTLC method was developed using pre-coated TLC plates (Merck) with silica gel G 60F(254). The optimized mobile phase was toluene-chloroform-ethanol (4:4:2, V/V), having UV detection at 266 nm. Forced degradation study was carried out using various stressors like acidic, alkaline, hydrolytic, oxidative, photolytic and thermal conditions (International Council for Harmonisation [ICH], Q1A [R2]). Leflunomide was susceptible to degradation in acidic, alkaline and neutral stressors, whereas minor degradation was observed in oxidative, photolytic and thermal stressors. Degradation products of acidic and alkaline conditions were characterized by high-resolution mass spectrometry (HR-MS). Degradation products identified after stress studies were 4-(trifluoromethyl)aniline and 5-methylisoxazole-4-carboxylic acid. Linearity studies were performed in the range of 100-600 ng/band. The parametric statistics of the calibration curve was found to be 0.9988. The limit of detection and limit of quantification values were found to be 4.35 ng/band and 13.19 ng/band. The developed method was studied as per the ICH Q2 (R1) guidelines for different parameters like linearity, accuracy, precision, specificity and robustness. Leflunomide in tablet dosage form was successfully analyzed using the described approach.
引用
收藏
页码:635 / 641
页数:7
相关论文
共 17 条
  • [11] Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography
    Schmidt, A
    Schwind, B
    Gillich, M
    Brune, K
    Hinz, B
    [J]. BIOMEDICAL CHROMATOGRAPHY, 2003, 17 (04) : 276 - 281
  • [12] STABILITY INDICATING HPLC METHOD DEVELOPMENT: A REVIEW
    Shah, Bhoomi P.
    Jain, Suresh
    Prajapati, Krishna K.
    Mansuri, Nasimabanu Y.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2012, 3 (09): : 2978 - 2988
  • [13] Sola KA., 2017, INT J DRUG REGUL AFF, V5, P60, DOI [10.22270/ijdra.v5i4.210, DOI 10.22270/IJDRA.V5I4.210]
  • [14] Soneji PD., 2015, INT J PHARM TECHNOL, V6, P7500
  • [15] United States Pharmacopeia, 2014, 38 NAT FORM 33 US PH, P395
  • [16] Yadav B., 2010, J GLOB PHARMA TECHNO, V2, P40
  • [17] Determination of leflunomide in tablets by high performance liquid chromatography
    Yeniceli, D
    Dogrukol-Ak, D
    Tuncel, M
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 40 (01) : 197 - 201